Literature DB >> 20140116

Erlotinib (tarceva) for the treatment of non-small-cell lung cancer and pancreatic cancer.

Caio M Rocha-Lima, Luis E Raez.   

Abstract

Erlotinib (Tarceva) is a small-molecule, orally dosed, anti-cancer drug that inhibits the epidermal growth factor receptor. Randomized, controlled clinical studies have demonstrated that erlotinib significantly improved survival in patients with previously treated non-small-cell lung cancer and, in combination with chemotherapy, in patients with untreated pancreatic cancer. In this article, we describe the clinical evidence and value of erlotinib as a therapy for non-small-cell lung cancer and pancreatic cancer and discuss ongoing clinical studies to optimize its use in various settings and to identify appropriate patient populations.

Entities:  

Keywords:  EGFR mutation; erlotinib; non-small-cell lung cancer; pancreatic cancer

Year:  2009        PMID： 20140116      PMCID： PMC2799146     

Source DB:  PubMed          Journal:  P T        ISSN： 1052-1372


  41 in total

1.  Comparative clinical and economic outcomes of treatments for refractory non-small cell lung cancer (NSCLC).

Authors:  Josh J Carlson; Carolina Reyes; Nina Oestreicher; Deborah Lubeck; Scott D Ramsey; David L Veenstra
Journal:  Lung Cancer       Date:  2008-03-04       Impact factor: 5.705

2.  Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial.

Authors:  H A Burris; M J Moore; J Andersen; M R Green; M L Rothenberg; M R Modiano; M C Cripps; R K Portenoy; A M Storniolo; P Tarassoff; R Nelson; F A Dorr; C D Stephens; D D Von Hoff
Journal:  J Clin Oncol       Date:  1997-06       Impact factor: 44.544

3.  Randomized phase III trial of docetaxel versus vinorelbine or ifosfamide in patients with advanced non-small-cell lung cancer previously treated with platinum-containing chemotherapy regimens. The TAX 320 Non-Small Cell Lung Cancer Study Group.

Authors:  F V Fossella; R DeVore; R N Kerr; J Crawford; R R Natale; F Dunphy; L Kalman; V Miller; J S Lee; M Moore; D Gandara; D Karp; E Vokes; M Kris; Y Kim; F Gamza; L Hammershaimb
Journal:  J Clin Oncol       Date:  2000-06       Impact factor: 44.544

4.  Evaluation of erlotinib in advanced non-small cell lung cancer: impact on the budget of a U.S. health insurance plan.

Authors:  Scott D Ramsey; Lauren Clarke; Tripthi V Kamath; Deborah Lubeck
Journal:  J Manag Care Pharm       Date:  2006 Jul-Aug

5.  A phase I study of erlotinib in combination with gemcitabine and radiation in locally advanced, non-operable pancreatic adenocarcinoma.

Authors:  A Duffy; J Kortmansky; G K Schwartz; M Capanu; S Puleio; B Minsky; L Saltz; D P Kelsen; E M O'Reilly
Journal:  Ann Oncol       Date:  2007-09-17       Impact factor: 32.976

6.  Final survival and safety results from a multicenter, open-label, phase 3b trial of erlotinib in patients with advanced nonsmall cell lung cancer.

Authors:  David R Spigel; Ming Lin; Vincent O'Neill; John D Hainsworth
Journal:  Cancer       Date:  2008-06-15       Impact factor: 6.860

7.  Clinical course of patients with non-small cell lung cancer and epidermal growth factor receptor exon 19 and exon 21 mutations treated with gefitinib or erlotinib.

Authors:  Gregory J Riely; William Pao; Duykhanh Pham; Allan R Li; Naiyer Rizvi; Ennapadam S Venkatraman; Maureen F Zakowski; Mark G Kris; Marc Ladanyi; Vincent A Miller
Journal:  Clin Cancer Res       Date:  2006-02-01       Impact factor: 12.531

8.  Phase III study of erlotinib in combination with cisplatin and gemcitabine in advanced non-small-cell lung cancer: the Tarceva Lung Cancer Investigation Trial.

Authors:  Ulrich Gatzemeier; Anna Pluzanska; Aleksandra Szczesna; Eckhard Kaukel; Jaromir Roubec; Flavio De Rosa; Janusz Milanowski; Hanna Karnicka-Mlodkowski; Milos Pesek; Piotr Serwatowski; Rodryg Ramlau; Terezie Janaskova; Johan Vansteenkiste; Janos Strausz; Georgy Moiseevich Manikhas; Joachim Von Pawel
Journal:  J Clin Oncol       Date:  2007-04-20       Impact factor: 44.544

9.  KRAS mutation is an important predictor of resistance to therapy with epidermal growth factor receptor tyrosine kinase inhibitors in non-small-cell lung cancer.

Authors:  Erminia Massarelli; Marileila Varella-Garcia; Ximing Tang; Ana C Xavier; Natalie C Ozburn; Diane D Liu; Benjamin N Bekele; Roy S Herbst; Ignacio I Wistuba
Journal:  Clin Cancer Res       Date:  2007-05-15       Impact factor: 12.531

Review 10.  The risk of febrile neutropenia in patients with non-small-cell lung cancer treated with docetaxel: a systematic review and meta-analysis.

Authors:  A Wailoo; A Sutton; A Morgan
Journal:  Br J Cancer       Date:  2009-02-10       Impact factor: 7.640
View more
  9 in total

1.  Novel derivatives of anaplastic lymphoma kinase inhibitors: Synthesis, radiolabeling, and preliminary biological studies of fluoroethyl analogues of crizotinib, alectinib, and ceritinib.

Authors:  Bhasker Radaram; Federica Pisaneschi; Yi Rao; Ping Yang; David Piwnica-Worms; Mian M Alauddin
Journal:  Eur J Med Chem       Date:  2019-08-09       Impact factor: 6.514

Review 2.  Oncolytic virotherapy for pancreatic cancer.

Authors:  Sonia Wennier; Shoudong Li; Grant McFadden
Journal:  Expert Rev Mol Med       Date:  2011-05-18       Impact factor: 5.600

3.  HMGA-targeted phosphorothioate DNA aptamers increase sensitivity to gemcitabine chemotherapy in human pancreatic cancer cell lines.

Authors:  Miki Watanabe; Sulaiman Sheriff; Kenneth B Lewis; Stuart L Tinch; Junho Cho; Ambikaipakan Balasubramaniam; Michael A Kennedy
Journal:  Cancer Lett       Date:  2011-10-10       Impact factor: 8.679

Review 4.  Bugs and drugs: oncolytic virotherapy in combination with chemotherapy.

Authors:  Sonia Tusell Wennier; Jia Liu; Grant McFadden
Journal:  Curr Pharm Biotechnol       Date:  2012-07       Impact factor: 2.837

5.  PTPRT epigenetic silencing defines lung cancer with STAT3 activation and can direct STAT3 targeted therapies.

Authors:  Malabika Sen; Audrey Kindsfather; Ludmila Danilova; Feng Zhang; Raffaele Colombo; Matthew G LaPorte; Brenda F Kurland; Donna M Huryn; Peter Wipf; James G Herman
Journal:  Epigenetics       Date:  2019-10-13       Impact factor: 4.528

6.  High frequency of exon 20 S768I EGFR mutation detected in malignant pleural effusions: A poor prognosticator of NSCLC.

Authors:  George D'Souza; Chirag Dhar; Vishal Kyalanoor; Lokendra Yadav; Mugdha Sharma; Mohammad Nawaz S; Sweta Srivastava
Journal:  Cancer Rep (Hoboken)       Date:  2020-08-06

7.  Pharmacokinetic properties of two erlotinib 150 mg formulations with a genetic effect evaluation in healthy Korean subjects.

Authors:  Hyun-Gyu Choi; Ji-Young Jeon; Yong-Jin Im; Yunjeong Kim; Eun-Kee Song; Young-Hwan Seo; Seok-Je Cho; Min-Gul Kim
Journal:  Clin Drug Investig       Date:  2015-01       Impact factor: 3.580

Review 8.  Oncolytic viral therapy for pancreatic cancer: current research and future directions.

Authors:  Justin W Ady; Jacqueline Heffner; Elizabeth Klein; Yuman Fong
Journal:  Oncolytic Virother       Date:  2014-02-17

9.  PI16 attenuates response to sorafenib and represents a predictive biomarker in hepatocellular carcinoma.

Authors:  Pusen Wang; Zhongyi Jiang; Xueni Liu; Kanru Yu; Chunguang Wang; Hao Li; Lin Zhong
Journal:  Cancer Med       Date:  2020-08-10       Impact factor: 4.452
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.